Customized Specimen Collection Kits Provide Convenience, Accuracy and Promotion Ideal for Post-Marketing Studies
Rochester, NY, Sept. 22, 2008 – ACM-Pivotal <http://www.acm-pivotal.com/> , the global central laboratory that continually defines the customer-service standard with its flexible approach, is now offering its unique KitKaddySM and lab collection kits to pharmaceutical, biotech and contract research organizations (CROs) that want to promote their brand at the physician level. The environmentally-friendly diagnostic specimen kits have been designed as easy-to-use space savers that help standardize collection across sites and countries. Companies can provide their logo, colors and additional brand elements to be printed on the kits, which will be housed at investigator sites throughout a clinical trial.
ACM-Pivotal will be showcasing its KitKaddy and collection kits, along with its safety testing expertise, at the 11th Registries and Post Approval Studies Congress <http://www.acm-pivotal.com/Registries_contact.html> in Washington, DC Sept. 23-25. The conference agenda is aimed at post-approval studies for improved safety and risk assessment.
ACM-Pivotal has been shipping KitKaddy and lab collection kits to investigator sites globally since 2003 and has received positive response from both investigators and sponsors. Customer demand and increased post-marketing studies have prompted ACM-Pivotal to offer a white-labeled solution to help increase brand awareness of new drugs available on the market.
“Our KitKaddy and lab collection kits are now multipurpose. Not only are they ideal for large safety studies, they provide an additional avenue for sponsors to reinforce their brands to a key audience,” said Elena Logan, VP, Clinical Trials. “With the continued emphasis on post-marketing safety studies, we are pleased to have a solution that is very well aligned with these commitments.”
The KitKaddy is organized with 24 custom visit and protocol-specific laboratory supply trays with the capacity to support large safety studies. Designed specifically for each clinical trial, all the necessary draw supplies are included. ACM-Pivotal’s collection kits enable clinicians to easily adhere to the specimen collection portion of protocols. Furthermore, the kits are assembled in a facility using 100 percent wind energy and manufactured using paperboard that is 100 percent recyclable and made from a renewable resource. The high-quality kits are produced in an ISO 9002 certified facility.
For more information and photos, please visit http://www.acm-pivotal.com/news_KitKaddy_9_22_08.html
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.